CEO of Ozempic Maker Grilled on Weight Loss Drug Pricing Amid Rising Costs

Rising Costs of Weight Loss Drugs Hurt Consumers

Many Americans struggle to pay for weight loss medications due to rising costs and changes in insurance coverage. For some, these drugs significantly improve health. For example, Debbie Halstead from West Virginia lost 60 pounds using Wegovy, a glucagon-like peptide 1 (GLP-1) drug, but her monthly cost is set to jump from $25 to $713 in January due to insurance changes.

Halstead noted, "Even if I didn’t lose another pound, I’d take this drug as long as I could. But at $700 a month, that’s not going to happen." She is one of many facing higher expenses as insurers reassess coverage. Some states, like North Carolina, have stopped covering weight loss drugs altogether.

Currently, only about one-third of patients prescribed weight-loss medications keep taking them long-term. These drugs are often meant to be taken for life. When patients stop the medications, they usually regain weight. Despite high demand, many working-age Americans can’t afford these treatments.

Insurance Coverage Issues

Insurance companies vary in how they cover weight loss drugs. Some Blue Cross Blue Shield plans no longer cover these medications for weight loss, citing costs. A mere 1% of Affordable Care Act marketplace plans provide coverage for anti-obesity drugs. Medicare also restricts coverage for these medications to patients with specific health conditions.

Dr. Angela Fitch of the Obesity Medicine Association highlighted insurance coverage as a major barrier. She stated, “This gap in coverage should be considered immoral.” Halstead received a notice from Blue Cross Blue Shield about her upcoming cost increase, prompting her to search for coupons.

Blue Cross Blue Shield Association stated it regularly evaluates drug coverage, leading to changes each year. However, while 44% of large employers cover GLP-1 drugs for obesity, just 5% allow these without restrictions.

Consumer Alternatives

Due to high prices, some consumers seek alternatives. For instance, Amanda Bonello from Iowa turned to a compounded version of the drug tirzepatide, as her insurance wouldn’t cover the brand-name version, costing over $1,000. She paid $211 for a compounded version and lost 18 pounds.

The FDA allows compounding pharmacies to provide alternatives when drugs are in short supply. However, the recent FDA ruling that Zepbound and Mounjaro are no longer in short supply raises concerns about the future of compounded alternatives. Bonello and others rely on these less expensive options.

This situation highlights broader issues: many people cannot afford brand-name drugs. The government’s decision on drug pricing could alleviate the burden for millions. As weight-loss drug costs continue to rise, consumers call for more affordable options and accessible health care solutions.